Novartis, P&G enter agreement for OAB drug

July 21, 2005

Novartis Pharmaceuticals Corp. and Proctor & Gamble Pharmaceuticals, Inc. have entered into an agreement for the co-promotion and further development of darifenacin (Enablex) extended-release tablets for the treatment of overactive bladder in the United States.

Novartis Pharmaceuticals Corp. and Proctor & Gamble Pharmaceuticals, Inc. have entered into an agreement for the co-promotion and further development of darifenacin (Enablex) extended-release tablets for the treatment of overactive bladder in the United States. Novartis will continue to record revenues for the drug and will pay royalties to Proctor & Gable based on the product's performance.

In related news, Indevus Pharmaceuticals, Inc. has announced the closing of a previously announced sale of the marketing rights for trospium chloride (Sanctura) from Odyssey Pharmaceuticals, Inc. to Esprit Pharma Holding Co., Inc. Esprit Pharma is a recently formed, privately held pharmaceutical company.